Healthcare Industry News:  ExtraCorporeal Circulation 

Devices Cardiology

 News Release - February 24, 2009

Sorin Group Announces Start of Patient Enrolment in 'Perceval S' Sutureless Aortic Valve Clinical Trial in Europe

MILAN, Italy--(HSMN NewsFeed)--Sorin Group, (MIL:SRN), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today the enrolment of the first three patients in a clinical trial aimed at obtaining European market approval for its ‘Perceval S’ Sutureless Aortic Heart Valve.

In a previous pilot study (First-In-Man), 30 patients at high surgical risk were enrolled in three European centres.

The new Perceval S clinical trial will involve some 150 patients at high surgical risk in 9 centres throughout Europe.

The first three implants of the clinical trial were performed at the Institut Mutualiste Montsouris (IMM) in Paris.

“We successfully implanted the first three patients in this important trial. I was able to appreciate the innovative characteristics of the device in terms of safety, procedural success and clinical outcome”, commented Professor François Laborde, Chief of Cardiac Surgery at the IMM hospital. “This valve allows the removal of the diseased valve, precise positioning and fast release and implantation, and therefore, ultimately a significant reduction of surgical time,” he added.

The Sorin Group Perceval S Sutureless Aortic Heart Valve is a bioprosthesis made of a bovine pericardial tissue assembled on a super-elastic metal alloy stent. Buillding on the Pericarbon Freedom™ Valve, a well-established Sorin Group pericardial stentless valve in the European market since 1991, the Perceval valve features a unique stent design.

“This breakthrough prosthesis is designed to be implanted using a quick metal stent deployment technique thus obviating the need for using time-consuming, conventional suturing techniques. The success behind Sorin's heart valve lies in the Group's in-house competencies in stent research and development as well as its historic prominence in heart-valve development and production. We are confident that Perceval S Sutureless Aortic Heart Valve will set a new standard in the Aortic Valve Replacement,” said André-Michel Ballester, CEO, Sorin Group.

About the Perceval S Sutureless Aortic Heart Valve

Key benefits of the Perceval S valve are:
  • Reduced implantation time vs. conventional stented aortic valves
  • Well-established bovine pericardial valve
  • Super-elastic metal alloy stent
  • Optimal aortic wall anchoring and sealing
  • Exclusive detoxification treatment
  • Ready for use, no rinsing required
About the Sorin Group

The Sorin Group (, is a global medical device company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,500 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (ExtraCorporeal Circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.

For more information, please visit:

Source: Sorin Group

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.